BCKDK rs14235 A allele is associated with milder motor impairment and altered network topology in Parkinson’s disease

Zhichun Chen, Bin Wu, Guanglu Li, Liche Zhou, Lina Zhang, Jun Liu
doi: https://doi.org/10.1101/2023.07.20.23292985

Abstract

Background A multitude of genetic variants confer a risk of Parkinson’s disease (PD), however, whether these risk variants affected the motor symptoms of PD patients remain largely elusive. The objective of this study is to investigate the effects of BCKDK rs14235 (G > A), a risk variant associated with PD risk, on the motor manifestations and brain networks of PD patients.

Methods PD patients (n = 146) receiving magnetic resonance imaging from Parkinson’s Progression Markers Initiative (PPMI) database were investigated. The effects of BCKDK rs14235 on the motor manifestations and brain networks of PD patients were systematically evaluated.

Results BCKDK rs14235 A allele was associated with milder motor symptoms in PD patients. BCKDK rs14235 significantly modified the topology of brain structural and functional network. The assortativity in structural network was negatively associated with rigidity in PD while the shortest path length of right pallidum was positively associated with Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) scores. The mediation analysis suggested that assortativity in structural network mediated the effects of BCKDK rs14235 on rigidity and the shortest path length of right pallidum mediated the effects of BCKDK rs14235 on UPDRS-III scores.

Conclusions BCKDK rs14235 significantly shaped the motor impairment and network topology of PD patients. Differential network metrics mediated the effects of BCKDK rs14235 on rigidity and UPDRS-III scores of PD patients. Future studies were required to identify the molecular mechanisms underlying the effects of BCKDK rs14235 on motor impairment and brain network metrics of PD patients.

Introduction

Parkinson’s disease (PD) is the most common movement disorder in the world 1. Bradykinesia, rigidity, static tremor, postural impairment, and gait disabilities were the typical motor manifestations in PD patients 1. Although the loss of dopaminergic neurons was generally thought to be the major culprit resulting in motor impairment in PD, the mechanisms underlying the degeneration of dopaminergic neurons remain largely elusive 1. According to previous literature, both environmental and genetic factors contribute to dopaminergic neurodegeneration in PD 2–8, however, the occurrence of PD in most individuals is considered to be idiopathic with an unknown cause. Currently, hundreds of genetic loci conferring a risk of PD have been identified5,6, nevertheless, the neural mechanisms underlying the pathophysiology of these risk loci for PD are mainly unknown. Decoding the pathophysiology of PD from the perspective of genetics has recently become the mainstream study area as a result of the identification of new risk loci 5–7. Recently, new research breakthroughs in PD have been driven by the discovery of the biological functions of PD risk genes and their roles in the occurrence and development of PD at molecular, cellular, neural circuit and behavior levels 9–16. Over the last decade, a number of genes associated with PD risk, including SNCA14,17–19, PRKN9–12, LRRK220–25, PINK1 11–13, TMEM175 16, GPNMB 26,27, and ATP13A2 15, have been studied, both in terms of physiological and pathological functions. These discoveries have expanded our understanding of the neurodegenerative process in PD and identified key mechanisms by which we can identify potential therapeutic targets.

There is mounting evidence that the clinical characteristics of individuals with PD were diverse and intricate, presenting a significant obstacle to the clinical diagnosis and management in PD patients 28–31. Previous studies suggest that genetic variations modify age at onset 32,33, influence motor progression 34–36, and alter the frequency of a variety of nonmotor symptoms 37–39. Specifically, a multitude of mutated genes, such as GBA 36,38,39, LRRK2 24,40,41, PRKN 42,43, PINK1 43,44, SNCA 41,45 have been proven to alter the diverse range of symptoms experienced by individuals with familial PD. Therefore, genetic variations significantly contributed to the clinical heterogeneity of PD patients. For example, it has been shown that individuals harboring GBA variants encountered an earlier age at onset and exhibited more pronounced motor and nonmotor symptoms in comparison to individuals without GBA variants 46,47. According to previous studies, the motor impairment of PD patients were linked to several variants, including GBA 46,47, SNCA 48,49, BST1 50, ATP8B2 51, PARK16 52, GCH1 53, and APOE 54. Recently, we revealed 3 PD-risk associated genetic variants, BCKDK rs14235, CCDC62 rs11060180, and GCH1 rs11158026, were significantly associated with motor function, which was measured by Unified Parkinson’s Disease Rating Scale part III (UPDRS-III), in PD patients from Parkinson’s Progression Markers Initiative (PPMI) database 55. In fact, the effects of GCH1 rs11158026 on motor decline of PD patients have been demonstrated by a previous study 53. These findings suggested that the motor manifestations of PD patients were significantly shaped by genetic variations. However, the neural mechanisms underlying the effects of these genetic variants on motor function remain largely unknown. We have recently demonstrated that motor and nonmotor symptoms in PD patients were significantly related to brain structural and functional network metrics 37,55,56. Additionally, we have shown that the effect of MAPT rs17649553 on PD patients’ verbal memory was mediated by the small-worldness metrics of white matter network 37. Furthermore, we also reported that the effects of CCDC62 rs11060180 on motor function of PD patients were mediated by the small-world topology in gray matter covariance network 55. Hence, PD risk-associated genetic variants may shape the motor and non-motor symptoms by influencing the structural and functional networks of PD patients 37,55.

BCKDK rs14235 (G > A) was associated with increased PD risk 5,6 and significantly modified the motor function of PD patients 55. In this study, we reasoned that BCKDK rs14235 may also modify brain network metrics and network metrics shaped by BCKDK rs14235 may mediate the effects of BCKDK rs14235 on motor function. Therefore, the objective of current study is to evaluate whether BCKDK rs14235 affects the structural and functional brain networks of PD patients and to examine whether network metrics shaped by BCKDK rs14235 mediate its associations with motor impairment of PD patients. Specifically, our goals consist of: (i) investigate whether BCKDK rs14235 A allele is associated scores of motor assessments in PD patients using association analysis; (ii) examine whether structural and functional network measurements vary significantly between GG carriers and A-carriers (GA and AA carriers); (iii) assess whether the effects of BCKDK rs14235 on graphical network metrics were independent of common confounding variables, such as age, sex, and disease duration; and (iv) evaluate whether the structural network and functional network measurements mediate the impacts of BCKDK rs14235 on motor function of PD patients.

Materials and Methods

Participants

The data used in this study were acquired from PPMI cohort study. The PPMI study was approved by Institutional Review Board of each participating site. The informed consents were signed from all participants and could be obtained from the investigators of each participating site. The PD patients were included if they met the criteria below: (i) The patients aged over 30 years old and had a disease duration within 2 years; (ii) The patients had a diagnosis of PD according to the Movement Disorders Society (MDS) Clinical Diagnostic Criteria for PD; (iii) The patients received 3D T1-weighted MPRAGE imaging, resting-state fMRI imaging, and diffusion tensor imaging (DTI) during the same period; (iv) The PD patients received motor assessments including Hoehn and Yahr (H&Y) stages, tremor scores, rigidity scores, and the MDS Unified Parkinson’s Disease Rating Scale part III (MDS-UPDRS). The PD patients were excluded if they met the exclusion criteria below: (i) The patients showed structural abnormalities in the T1-weighted or T2-weighted MRI; (ii) The patients were diagnosed to have PD dementia or dementia with Lewy bodies based on the MDS criteria; (iii) The patients were found to carry the genetic mutations of familial PD or were from the genetic PPMI cohort and prodromal cohort. Finally, one hundred and forty-six PD patients receiving DTI images (n = 146) were included in this study. Among these patients, eighty-three of them (n = 83) also underwent functional MRI. To decipher the associations between BCKDK rs14235 (G > A) and motor assessments or brain network metrics, the whole-exome sequencing of blood DNA samples was performed to obtain the genotypes of BCKDK rs14235 for individual participant. The demographic and clinical characteristics in different genotype groups (CC carriers, CT carriers, TT carriers) of BIN3 rs2280104 were compared and shown in Table 1.

View this table:
Table 1 The demographic and clinical data for different genotype groups of BCKDK rs14235

Image acquisition

The 3D T1-weighted MRI images, resting-state functional images, and DTI images were acquired using 3T Siemens (TIM Trio and Verio) scanners (Erlangen, Germany). The MRI parameters for 3D T1 images were shown below: TR = 2300 ms, TE = 2.98 ms, Voxel size = 1 mm3, Slice thickness =1.2 mm, twofold acceleration, sagittal-oblique angulation. The DTI was performed with the parameters as follows: TR= 8,400-8,800 ms, TE = 88 ms, Voxel size = 2 mm3, Slice thickness = 2 mm, 64 directions, b = 1000 s/mm2. The resting-state functional images were performed using a T2*-weighted echo planar imaging (EPI) sequence as shown below: TR = 2400 ms, TE = 25 ms, Voxel size = 3.3 mm3, Slice number = 40, Slice thickness = 3.3 mm, Flip angle = 90°, Acquisition time = 8 min.

Imaging preprocessing

The DTI images were preprocessed using FMRIB Software Library toolbox (FSL, https://fsl.fmrib.ox.ac.uk/fsl/fslwiki). Briefly, DTI images were corrected for head motions, eddy current distortions, and susceptibility artifacts resulted from magnetic field inhomogeneity. The fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity, and radial diffusivity maps were computed according to the methods as previously reported. The processed images were then reconstructed in standardized MNI space for the following structural network construction.

The SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12/) and GRETNA software (https://www.nitrc.org/projects/gretna/) were utilized for the preprocessing of resting-state functional images. The detailed preprocessing procedures for functional images included: slice-timing correction, spatial normalizing with standard EPI template, spatial smoothing with 4-mm Gaussian kernel, removal of nuisance signals, and temporal bandpass filtering (0.01–0.1 Hz). The participants (n = 9) with head motion frame-wise displacement (FD) > 0.5 mm and head rotation > 2° were excluded due to excessive head motions according to previous studies 57–60. In addition, the head motion parameters were adjusted to correct the effects of head motions on the functional images. Furthermore, we also guaranteed that there were no significant differences in FD values between the GG carriers and T-carriers of BCKDK rs14235 (p > 0.05).

Network construction

As previously reported 37,56, the white matter network was constructed using deterministic fiber tractography implemented in PANDA (http://www.nitrc.org/projects/panda/), a free and open MATLAB software. The Fiber Assignment by Continuous Tracking (FACT) algorithm was utilized to derive the whole-brain white matter fibers between each pair of 90 nodes in the AAL atlas. The threshold for mean FA skeleton was set to FA > 0.20 and the threshold for white matter fiber angle was set to 45°. As a result, fiber number-based white matter network matrices were constructed in conformity with AAL atlas.

The steps for the construction of functional connectivity matrices were as follows. Firstly, AAL atlas was used to define 90 cortical and subcortical nodes in functional network. Secondly, Pearson correlation coefficient was computed for the time series of 90 nodes to represent the pairwise function connectivity. Finally, the correlation coefficients in functional connectivity matrices were Fisher’s r-to-z transformed to improve the normality of functional connectivity.

Graph-based network analysis

The GRETNA (https://www.nitrc.org/projects/gretna/) linked with MATLAB software was sued to calculate the graphical network metrics of structural and functional 61. During the calculation of global and nodal network metrics, a range of network sparsity thresholds (0.05 ∼ 0.50 with an interval of 0.05) were established. The area under curve (AUC) of global and nodal network metrics was also computed. The global network characteristics consisted of: assortativity, hierarchy, global efficiency, local efficiency, and small-worldness metrics. The small-worldness metrics consisted of: clustering coefficient (Cp), characteristic path length (Lp), normalized clustering coefficient (γ), normalized characteristic path length (λ), and small worldness (σ). The nodal network characteristics include: nodal betweenness centrality, nodal degree centrality, nodal Cp, nodal efficiency, nodal local efficiency, and nodal shortest path length (SPL). The definitions of the aforementioned network metrics have been reported by previous investigations 55,62,63.

Statistical analysis

Comparison of clinical variables

For comparisons of continuous variables, unpaired t-test (GG carriers vs A-carriers) and one-way ANOVA test followed by false discovery rate (FDR) correction (GG carriers vs GA carrier vs AA carriers) were used. For comparisons of categorical variables, χ2 test was used. p < 0.05 was considered statistically significant.

Comparison of global network strength

Network-Based Statistic (NBS, https://www.nitrc.org/projects/nbs/) software was used to compare the global network strength of structural and functional networks in different genotype groups of BCKDK rs14235 64. The covariates, including age, sex, years of education, and disease duration were included during NBS analysis. p < 0.05 after FDR correction was considered statistically significant 65.

Comparison of network metrics

Two-way ANOVA test followed by FDR corrections was used for the comparisons of global and nodal network metrics among different genotype groups of BCKDK rs14235. p < 0.05 after FDR correction was considered statistically significant. The AUCs of global network metrics among different genotype groups of BCKDK rs14235 were compared using one-way ANOVA test followed by FDR corrections. p < 0.05 was considered statistically significant.

Association analysis between genotype and scores of motor assessments

The Pearson correlation and multivariate regression analysis were used to analyze the associations between genotype of BCKDK rs14235 and scores of motor assessments. During the multivariate regression analysis, age, sex, disease duration, and years of education were included as covariates. p < 0.05 was considered statistically significant.

Association analysis between genotype and graphical network metrics

The multivariate regression analysis was utilized to analyze the associations between genotype of BCKDK rs14235 and graphical network metrics with age, sex, disease duration, and years of education as covariates. FDR-corrected p < 0.05 was considered statistically significant.

Association analysis between graphical metrics and scores of motor assessments

The Pearson correlation and multivariate regression analysis were used to analyze the associations between graphical metrics and scores of motor assessments. Age, sex, disease duration, and years of education were included as covariates during multivariate regression analysis. p < 0.05 was considered statistically significant.

Mediation analysis

IBM SPSS Statistics Version 26 was used to perform mediation analysis. The independent variable in the mediation model was the genotype of BCKDK rs14235. The dependent variables were the scores of rigidity or UPDRS-III. The mediators were graphical network metrics associated with scores of motor assessments. We modeled the mediated effects of graphical network metrics on the relationships between scores of motor assessments and genotype of BCKDK. During the mediation analysis, the age, sex, disease duration, and years of education were included as covariates. p < 0.05 was considered statistically significant.

Results

Allele and genotype frequencies

The allele frequencies (G allele frequency = 0.5993, A allele frequency = 0.4007) for BCKDK rs14235 were comparable to the data from Allele Frequency Aggregator Project (A allele frequency = 0.3798). The distribution of genotype frequencies from our patients didn’t deviate Hardy–Weinberg equilibrium (p > 0.10). Genotype frequencies were similar with respect to age or sex (p > 0.05).

Group difference of clinical variables and multivariate regression analysis

The group differences of clinical variables in different genotype groups of BCKDK rs14235 were shown in Table 1 and Figure 1. The Hoehn & Yahr stages and tremor scores were not statistically different between GG carriers and A-carriers (GA carriers and AA carriers). The rigidity scores and UPDRS-III scores were significantly lower in A-carriers compared to GG carriers (Table 1 and Figure 1). Consistently, the rigidity scores and UPDRS-III scores in GA carriers and AA carriers were also much lower than those of GG carriers (Table 1 and Figure 1). The BCKDK rs14235 A allele was negatively associated with rigidity scores (β = −1.0410, p < 0.01) and UPDRS-III scores (β = −3.3540, p < 0.01).

Figure 1.
Figure 1. Group differences of motor assessments between GG carriers and A-carriers of PD patients

(A) A-carriers exhibited lower rigidity scores compared to GG carriers. (B) GA and AA carriers showed lower rigidity scores compared to GG carriers. (C) A-carriers presented lower UPDRS-III scores compared to GG carriers. (D) GA and AA carriers showed lower UPDRS-III scores compared to GG carriers. Unpaired t-test (GG carriers vs A-carriers) and one-way ANOVA test followed by FDR corrections (GG carriers vs GA carrier vs AA carriers) were used. p < 0.05 was considered statistically significant. Abbreviations: UPDRS-III, Unified Parkinson’s Disease Rating Scale part III.

Group difference of graphical network metrics in structural network

Compared to GG carriers and GA carriers, AA carriers exhibited higher assortativity (FDR-corrected p < 0.05, sparsity range: 0.10 – 0.50; Figure 2A). Compared to GG carriers, AA carriers had lower small-worldness γ and σ (FDR-corrected p < 0.05, sparsity range: 0.15,0.30, 0.45-0.50; Figure 2A-C). Consistently, we also found higher AUC of assortativity in AA carriers compared to GG carriers and GA carriers (FDR-corrected p < 0.05; Figure S1A). Additionally, AA carriers exhibited lower AUCs of small-worldness γ and σ compared to GG and GA carriers (FDR-corrected p < 0.05; Figure S1B-C). For nodal metrics, AA carriers exhibited lower betweenness centrality in bilateral calcarine, left precuneus, and left thalamus compared to GG and GA carriers (FDR-corrected p < 0.05; Figure 2D). Compared to GG carriers, GA and AA carriers showed higher betweenness centrality, degree centrality, and nodal efficiency in right precuneus (FDR-corrected p < 0.05; Figure 2D, E, G). In addition, some key nodes in basal ganglia network, such as left putamen, right putamen, right pallidum also showed differential nodal network metrics among different genotype groups of BCKDK rs14235 (FDR-corrected p < 0.05; Figure 2D, E, G, I). Interestingly, AA carriers showed higher nodal Cp, nodal efficiency, and nodal local efficiency in right heschl compared to GG and GA carriers (FDR-corrected p < 0.05; Figure 2F-H).

Figure 2.
Figure 2. Group differences of structural network metrics among GG, GA, and AA carriers

(A-C) Group differences in assortativity (A), small-worldness γ (B), and small-worldness σ (C) among GG, GA, and AA carriers (FDR-corrected p < 0.05, Two-way ANOVA test). (D-I) Group differences in nodal betweenness centrality (D), degree centrality (E), Cp (F), efficiency (G), local efficiency (H), and SPL (I) among GG, GA, and AA carriers (FDR-corrected p < 0.05, Two-way ANOVA test). Two-way ANOVA test followed by FDR corrections (GG carriers vs GA carrier vs AA carriers) were used. p < 0.05 was considered statistically significant. Abbreviations: Cp, Clustering coefficient; γ, normalized clustering coefficient; σ, small worldness; SPL, shortest path length.

Group difference of graphical network metrics in functional network

Compared to GG carriers, GA and AA carriers exhibited higher global efficiency (FDR-corrected p < 0.05, sparsity range: 0.10-0.20; Figure 3A) and local efficiency (FDR-corrected p < 0.05, sparsity range: 0.05-0.15; Figure 3B) at multiple sparsity thresholds. In agreement with this, the AUCs of global efficiency and local efficiency were also higher in GA and AA carriers compared to GG carriers (FDR-corrected p < 0.05; Figure S1D-E). For nodal network metrics, AA carriers showed higher betweenness centrality in right middle fontal gyrus, right posterior cingulate gyrus, and bilateral precuneus compared to GA and GG carriers (FDR-corrected p < 0.05; Figure 3C). Moreover, AA carriers had higher degree centrality in right superior orbitofrontal gyrus and right posterior cingulate gyrus compared to GG and GA carriers (FDR-corrected p < 0.05; Figure 3D). Interestingly, network metrics of key nodes in basal ganglia network, including right caudate, left caudate, and right putamen were specifically modified by BCKDK rs14235 (FDR-corrected p < 0.05; Figure 3E-H). Furthermore, AA carriers exhibited higher nodal efficiency in bilateral posterior cingulate gyrus compared to GG carriers, companied by lower nodal SPL in AA carriers compared to GG carriers (FDR-corrected p < 0.05; Figure 3E and H). Taken together, these data supported that BCKDK rs14235 A allele enhanced the nodal network metrics of functional networks in PD.

Figure 3.
Figure 3. Group differences of functional network metrics among GG, GA, and AA carriers

(A-B) Group differences in global efficiency (A) and local efficiency (B) among GG, GA, and AA carriers (FDR-corrected p < 0.05, Two-way ANOVA test). (D-I) Group differences in nodal betweenness centrality (C), degree centrality (D), Cp (E), efficiency (F), local efficiency (G), and SPL (H) among GG, GA, and AA carriers (FDR-corrected p < 0.05, Two-way ANOVA test). Two-way ANOVA test followed by FDR corrections (GG carriers vs GA carrier vs AA carriers) were used. p < 0.05 was considered statistically significant. Abbreviations: Cp, Clustering coefficient; SPL, shortest path length.

The associations between BCKDK rs14235 and graphical network metrics

To examine whether the effects of BCKDK rs14235 on graphical network metrics were independent of common confounding variables, multivariate regression analysis was used to assess the associations between BCKDK rs14235 and graphical network metrics showing statistical group difference in Figure 2-3. As shown in Table S1 and Table S2, BCKDK rs14235 was significantly associated with multiple brain network metrics in both structural and functional networks (FDR-corrected p < 0.05; Table S1 and Table S2). These results demonstrated that BCKDK rs14235 independently shaped the network topology of both structural and functional network.

Mediation analysis

To explore whether graphical network metrics contributed to the effects of BCKDK rs14235 on motor impairment of PD patients, we analyzed the associations between graphical network metrics and rigidity scores or UPDRS-III scorers. Among those metrics showing significant group differences, AUC of assortativity in structural network was negatively associated with scores of rigidity (β = −1.29, p < 0.05; Figure 4A) while nodal SPL of right pallidum in structural network was positively associated with scores of UPDRS-III (β = 29.23, p < 0.01; Figure 4B). With mediation analysis, we further demonstrated that increased AUC of assortativity in structural network mediated the effects of BCKDK rs14235 on rigidity (Figure 4C). Additionally, lower nodal SPL in right pallidum in structural network mediated the effects of BCKDK rs14235 on UPDRS-III scores (Figure 4D).

Figure 4.
Figure 4. Mediation analysis suggested structural network metrics mediated the effects of BCKDK rs14235 on motor assessments of PD patients

(A) AUC of assortativity was negatively associated with the rigidity scores of PD patients (p < 0.05 in both Pearson correlation analysis and multivariate regression analysis). (B) Nodal SPL of right pallidum was positively associated with UPDRS-III scores in PD patients (p < 0.05 in both Pearson correlation analysis and multivariate regression analysis). (C) AUC of assortativity mediated the effects of BCKDK rs14235 on rigidity scores. (D) Nodal SPL of right pallidum mediated the effects of BCKDK rs14235 on UPDRS-III scores. The association analysis between network metrics and scores of motor assessments was conducted by Pearson correlation method and multivariate regression analysis with age, sex, disease duration, and years of education as covariates. During the mediation analysis, age, sex, disease duration, and years of education were included as covariates. p < 0.05 was considered statistically significant. Abbreviations: AUC, Area under curve; UPDRS-III, Unified Parkinson’s Disease Rating Scale part III; SPL, shortest path length.

Discussion

In this study, we revealed that a PD-associated risk variant, BCKDK rs14235, was outstandingly associated with scores of rigidity and UPDRS-III. In addition, BCKDK rs14235 prominently affected the network metrics of structural and functional network. Furthermore, differential structural network metrics were correlated with rigidity scores and UPDRS-III scores, respectively. Finally, we demonstrated that it was the increased AUC of assortativity and lower nodal SPL in right pallidum in structural network respectively mediated the effects of BCKDK rs14235 on rigidity scores and UPDRS-III scores.

The effects of BCKDK rs14235 on motor decline of PD patients

There is increasing consensus that PD is a neurodegenerative disorder with heterogeneous motor and non-motor features 28–31. According to previous literature, the heterogeneity of clinical manifestations was associated with age 56,66, sex 56,66, life styles 28,67,68, genetic variations 32,38,44,69, β-amyloid deposition 70, tau accumulation 70,71, varied pathological spread of synucleinopathy 28,70 and diverse degenerative thresholds 28,72. Genetic variations play an essential role in the modifications of clinical phenotypes of PD patients. Particularly, numerous mutated genes in PD, such as GBA 36,38,39, LRRK2 24,40,41, PRKN 42,43, PINK1 43,44, SNCA 41,45 have been demonstrated to significantly shape the clinical heterogeneity of familial PD patients. Motor symptoms of PD patients, on the other hand, were also influenced by genetic variations. It has been previously shown that the motor impairment of PD patients were linked to a series of genetic variants, including GBA 46,47, SNCA 48,49, BST1 50, ATP8B2 51, PARK16 52, GCH1 53, and APOE 54. Recently, we identified 3 genetic variants, CCDC62 rs11060180, GCH1 rs11158026 and BCKDK rs14235, were significantly associated with UPDRS-III scores in 198 PD patients 55. In current study, we confirmed that BCKDK rs14235 A allele was negatively associated with UPDRS-III scores in 146 PD patients. In addition, BCKDK rs14235 A allele was also associated with milder rigidity in PD patients, which further supported that BCKDK rs14235 specifically modified motor function of PD patients 55. Interestingly, BCKDK rs14235 A allele was not associated with tremor scores, suggesting that the effect of BCKDK rs14235 A allele was only limited to parts of motor symptoms, especially rigidity. Previous studies have reported that GCH1 rs11158026 T allele was associated with the impairment of dopaminergic innervation in striatum, which might help to explain why this allele was associated with higher UPDRS-III scores 53,55. In contrast, BCKDK rs14235 was not found to be associated with striatal binding ratios (SBRs) of bilateral striatum of PD patients 55, suggesting that the effects of BCKDK rs14235 on motor assessments were independent of striatum SBRs. Taken together, we concluded that BCKDK rs14235 was a PD risk-associated genetic variant specifically shaping the motor impairment of PD patients.

The effects of BCKDK rs14235 on structural network metrics

We found BCKDK rs14235 significantly modified the structural network metrics of PD patients. Compared to GG and GA carriers, AA carriers showed higher assortativity. Assortativity represents the tendency of nodes to connect with ‘similar’ nodes over ‘dissimilar’ nodes in a network. It has been shown that assortativity determined the robustness of a network to noise. For example, robustness is greatly enhanced in assortative neural networks 73. Additionally, robustness exhibits a noticeable increase as assortativity becomes more positive in gene regulatory networks 74. Furthermore, assortativity was also associated with higher synchronization in complex neuronal network 75.In current study, we found AA carriers with milder motor decline exhibited higher assortativity compared to GG and GA carriers, which suggested that AA carriers might have higher robustness to noise or random attacks due to their higher network assortativity. However, according to previous studies, PD patients seemed to exhibit increased assortativity 76–78, indicating higher assortativity may be associated with worse motor impairment in PD. One explanation for this discrepancy may be that these studies investigated the functional network and structural covariance network but not white matter network, which usually exhibited distinct topological properties compared to functional and structural covariance network 79–82. Small-world properties have been discovered in a multitude of biological networks, including gene regulatory network 83, microRNA functional networks 84, protein interaction network 85, and neural networks 86. Recently, we found MAPT rs17649553 T allele was associated with higher small-worldness properties in structural network and enhanced small-world topology in structural network mediated the effects of MAPT rs17649553 T allele on verbal memory of PD patients 37. In this study, we found AA carriers exhibited lower small-worldness γ and σ compared to GG carriers, indicating that small-world topology of structural network was specifically targeted by PD-associated risk variants 55. For nodal network metrics, we found network metrics of some key nodes in default mode network and basal ganglia network were preferentially modified. Precuneus was a key node in default mode network and was revealed to be impaired in PD patients. For example, precuneus atrophy and hypometabolism has been found in PD patients with isolated apathy 87. The disruption of functional connectivity and blood perfusion in precuneus was also reported by a series of studies 88–90. We found higher betweenness centrality, degree centrality, and nodal efficiency in right precuneus of AA carriers compared to GG carriers, indicating that local topology in right precuneus was specifically modulated by A allele of BCKDK rs14235. We found nodal network metrics in multiple key nodes of basal ganglia network, such as left putamen, right putamen, and right pallidum, were significantly modified, implying that basal ganglia network was preferentially regulated by A allele of BCKDK rs14235. Indeed, the alterations of nodal network metrics in putamen and pallidum have been revealed in PD patients 91,92. For instance, remarkable decreases of nodal efficiency have been observed in globus pallidus and putamen of PD patients 92. Recently, we showed that MAPT rs17649553 and BIN3 rs2280104 significantly modified betweenness centrality of left putamen 37,93, which indicated that left putamen was a shared target of PD-associated risk variants. Taken together, our findings demonstrated that structural network metrics were prominently shaped by BCKDK rs14235.

The effects of BCKDK rs14235 on functional network metrics

In addition to structural network, functional network was also significantly affected by BCKDK rs14235. We found higher global efficiency and local efficiency in AA and GA carriers compared to GG carriers, which suggested BCKDK rs14235 specifically modified network efficiency of functional network. In fact, compared to control participants, network local efficiency was significantly reduced in PD patients 94,95, whereas network global efficiency seemed to be increased in PD patients 95,96. Therefore, our findings indicated that BCKDK rs14235 might contribute to the disturbances of network efficiency in PD patients. We found nodal metrics in caudate, putamen, precuneus, and posterior cingulate gyrus were significantly modified by BCKDK rs14235, which suggested that similar to structural network, BCKDK rs14235 also preferentially shaped the local topology of basal ganglia network and default mode network in functional network of PD patients. The alterations of basal ganglia network and default mode network in PD have been demonstrated by several investigations 92,97–100. Thus, BCKDK rs14235 specifically shaped PD-related networks, especially basal ganglia network and default mode network. Interestingly, AA carriers showed consistently higher nodal betweenness centrality, degree centrality, nodal Cp, nodal efficiency, nodal local efficiency, and lower nodal SPL compared to GG and GA carriers, which suggested BCKDK rs14235 A allele was associated with enhanced functional network topology in comparison with G allele. In a recent study, we found BIN3 rs2280104 T-carriers exhibited lower nodal Cp, efficiency, local efficiency, and higher shortest path length in left caudate 93. In this study, we found higher nodal Cp, nodal local efficiency and lower nodal SPL in right caudate of AA carriers, which suggested local topology of caudate was specifically shaped by PD-associated risk variants93.Taken together, our findings demonstrated that functional network metrics were also dramatically modified by BCKDK rs14235.

The associations between network metrics and scores of motor assessments

We found structural network metrics were significantly associated with motor assessments of PD patients, indicating that structural network metrics were potential predictors of motor function in PD. In a recent study, we reported 3 genetic variants, GCH1 rs11158026, CCDC62 rs11060180, and BCKDK rs14235, were significantly correlated with UPDRS-III scores in PD patients 55, nevertheless, the neural mechanisms underlying the effects of these variants on UPDRS-III scores were not identified. According to a previous study, it seemed that GCH1 rs11158026 T allele contributed to the deterioration of motor function via the disruption of dopaminergic innervation in striatum 53. For CCDC62 rs11060180, we have recently demonstrated that small-world topology in gray matter covariance network mediated the effects of CCDC62 rs11060180 on motor assessments of PD patients 55. In this study, we showed that the lower nodal SPL of right pallidum, a key node in basal ganglia network, mediated the effects of BCKDK rs14235 on UPDRS-III scores. Pallidum, namely globus pallidus, was a core node in basal ganglia network, which played a key role in the occurrence of PD 101,102. In addition, pallidum was also an important target of neuromodulation in PD 103,104. Furthermore, the reduction of nodal efficiency in pallidum has been reported in PD patients, indicating impaired local information transfer efficiency in PD 92. In this study, we found significantly differential nodal network metrics in right pallidum among GG carriers, GA carriers, and AA carriers, characterized by higher nodal degree centrality and nodal efficiency, as well as lower nodal SPL in A-carriers. These results suggested that A-carriers exhibited higher information transfer efficiency in right pallidum compared to GG carriers, which provided reliable explanations at the network level for the negative association between BCKDK rs14235 A allele and UPDRS-III scores in PD patients. To summarize, we concluded that BCKDK rs14235 A allele delayed motor decline in PD by improving the local information transfer of right pallidum of structural network.

The potential molecular mechanisms underlying the effects of BCKDK rs14235

Branched-chain ketoacid dehydrogenase kinase (BCKDK) is a key rate-limiting enzyme catalyzing the oxidation of branched-chain amino acids 105,106. BCKDK was associated with a multitude of diseases, including cancer 105–107, nonalcoholic fatty liver disease 108, neurodevelopmental diseases 109–112, heart failure 113,114, and also PD 115,116. In this study, we found a genetic variant of BCKDK gene, rs14235 was significantly associated with motor assessments and network topology of PD patients, which suggested that BCKDK or branched-chain amino acid metabolism may be involved in the pathogenesis of PD. According to GTEx database, BCKDK rs14235 was associated with differential expressions of multiple genes in brain tissue, including KAT8, ZNF646, VKORC1, and BCKDK 55. Dang et al. (2022) revealed that KAT8 gene was causally associated with PD using dopaminergic neuron-specific eQTL in a mendelian randomization study 117. KAT8 has been shown to regulate PINK1-dependent mitophagy initiation and partially underlined the genetic risk for PD at 16q11.2 and MAPT H1 loci 118. Zinc finger (ZNF) gene family has been recently demonstrated to be associated with PD 119, such as ZNF219 and ZNF746, however, whether ZNF646 conferred a risk of PD remained elusive. VKORC1 gene has been shown to be associated with ischemic stroke 120, vascular dementia 121, and Alzheimer’s disease 122, whereas whether it was also associated with PD was unknown. On the basis of these findings, we concluded that the role of BCKDK gene in PD pathogenesis remained largely unknown. Future studies were required to decipher how BCKDK rs14235 affected disease risk, motor function, and network topology of PD patients.

Strengths and limitations of this study

In this study, we reported a PD-associated risk variant, BCKDK rs14235 was significantly associated with motor assessments and network topology of PD patients. This finding provided potential interpretations for the individual heterogeneity of motor symptoms in PD patients. In addition, our results also suggested that BCKDK rs14235 A allele is a genetic predictor of motor function in PD patients. The effects of BCKDK rs14235 on structural network and functional network indicated that BCKDK rs14235 significantly shaped the topological organizations of brain network. Particularly, BCKDK rs14235 A allele enhanced the local information transfer of right pallidum of structural network, which mediated the effects of BCKDK rs14235 A allele on motor assessment of PD patients. This provided plausible network mechanisms to explain the effects of BCKDK rs14235 A allele on motor decline of PD patients. The limitation of this study was that we did not determine the molecular mechanisms mediating the effects of BCKDK rs14235 on motor function and brain networks. Further studies are encouraged to decipher the impact of BCKDK rs14235 on PD pathogenesis at the molecular level.

Conclusions

To summarize, we reported a PD risk-associated genetic variant, BCKDK rs14235, was significantly associated with motor assessments of PD patients. In addition, we found BCKDK rs14235 A allele modified both structural network and functional network. Moreover, we further showed structural network metrics were significantly correlated with motor symptoms. Finally, we demonstrated that it was the local topology of right pallidum that mediated the effects of BCKDK rs14235 A allele on motor assessments of PD patients.

Author contributions

Zhichun Chen, Conceptualization, Formal analysis, Visualization, Methodology, Writing - original draft, Writing - review and editing; Bin Wu, Validation, Investigation, Methodology; Guanglu Li, Data curation, Formal analysis, Visualization; Liche Zhou, Data curation, Formal analysis, Investigation; Lina Zhang, Formal analysis, Investigation, Methodology; Jun Liu, Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing-review and editing.

Funding information

This work was supported by grants from National Natural Science Foundation of China (Grant No. 81873778, 82071415) and National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Grant No. NRCTM(SH)-2021-03).

Conflict of Interest

The authors have no conflict of interest to report.

Data availability

All the raw data used in the preparation of this Article were downloaded from PPMI database (www.ppmi-info.org/data). All data produced in the present study are available upon reasonable request to the authors.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Acknowledgments

Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmiinfo.org/data). We thank the share of PPMI data by all the PPMI study investigators. PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, which can be found at www.ppmiinfo.org/fundingpartners.

Reference

  1. 1.↵
    Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–2303.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Dunn AR, O’Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer’s disease and Parkinson’s disease. Neurosci Biobehav Rev. 2019;103:73–80.
    OpenUrlCrossRef
  3. 3.↵
    Georgiou A, Demetriou CA, Christou YP, et al. Genetic and Environmental Factors Contributing to Parkinson’s Disease: A Case-Control Study in the Cypriot Population. Front Neurol. 2019;10:1047.
    OpenUrl
  4. 4.
    Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014;46(9):989–993.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091–1102.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Chang D, Nalls MA, Hallgrimsdottir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet. 2017;49(10):1511–1516.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet. 2009;41(12):1303–1307.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–1272.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Manzanillo PS, Ayres JS, Watson RO, et al. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature. 2013;501(7468):512-516.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.
    Bingol B, Tea JS, Phu L, et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature. 2014;510(7505):370-375.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Matheoud D, Sugiura A, Bellemare-Pelletier A, et al. Parkinson’s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell. 2016;166(2):314–327.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Sliter DA, Martinez J, Hao L, et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018;561(7722):258-262.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Matheoud D, Cannon T, Voisin A, et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1(-/-) mice. Nature. 2019;571(7766):565-569.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Burmann BM, Gerez JA, Matecko-Burmann I, et al. Regulation of alpha-synuclein by chaperones in mammalian cells. Nature. 2020;577(7788):127-132.
    OpenUrlCrossRef
  15. 15.↵
    van Veen S, Martin S, Van den Haute C, et al. ATP13A2 deficiency disrupts lysosomal polyamine export. Nature. 2020;578(7795):419-424.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Wie J, Liu Z, Song H, et al. A growth-factor-activated lysosomal K(+) channel regulates Parkinson’s pathology. Nature. 2021.
  17. 17.↵
    Peng C, Gathagan RJ, Covell DJ, et al. Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature. 2018;557(7706):558-563.
    OpenUrlCrossRefPubMed
  18. 18.
    Fusco G, Chen SW, Williamson PTF, et al. Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. Science. 2017;358(6369):1440-1443.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating alpha-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578(7794):273-277.
    OpenUrl
  20. 20.↵
    Nguyen HN, Byers B, Cord B, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8(3):267–280.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.
    Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat Rev Neurosci. 2010;11(12):791–797.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.
    Watanabe R, Buschauer R, Bohning J, et al. The In Situ Structure of Parkinson’s Disease-Linked LRRK2. Cell. 2020;182(6):1508–1518 e1516.
    OpenUrlCrossRef
  23. 23.
    Deniston CK, Salogiannis J, Mathea S, et al. Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction. Nature. 2020;588(7837):344-349.
    OpenUrlCrossRef
  24. 24.↵
    Simuni T, Uribe L, Cho HR, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol. 2020;19(1):71–80.
    OpenUrlCrossRef
  25. 25.↵
    Liu SY, Wile DJ, Fu JF, et al. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson’s disease: a cross-sectional PET study. Lancet Neurol. 2018;17(4):309–316.
    OpenUrlCrossRef
  26. 26.↵
    Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson’s disease patients and increases after lysosomal stress. Neurobiol Dis. 2018;120:1–11.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Diaz-Ortiz ME, Seo Y, Posavi M, et al. GPNMB confers risk for Parkinson’s disease through interaction with alpha-synuclein. Science. 2022;377(6608):eabk0637.
    OpenUrlCrossRef
  28. 28.↵
    Berg D, Borghammer P, Fereshtehnejad SM, et al. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat Rev Neurol. 2021;17(6):349–361.
    OpenUrlCrossRef
  29. 29.
    Carceles-Cordon M, Weintraub D, Chen-Plotkin AS. Cognitive heterogeneity in Parkinson’s disease: A mechanistic view. Neuron. 2023;111(10):1531–1546.
    OpenUrl
  30. 30.
    Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385–397.
    OpenUrlCrossRef
  31. 31.↵
    Weintraub D, Aarsland D, Chaudhuri KR, et al. The neuropsychiatry of Parkinson’s disease: advances and challenges. Lancet Neurol. 2022;21(1):89–102.
    OpenUrlCrossRef
  32. 32.↵
    Grover S, Kumar Sreelatha AA, Pihlstrom L, et al. Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium. Neurology. 2022;99(7):e698–e710.
    OpenUrl
  33. 33.↵
    Li C, Ou R, Chen Y, et al. Genetic Modifiers of Age at Onset for Parkinson’s Disease in Asians: A Genome-Wide Association Study. Mov Disord. 2021;36(9):2077–2084.
    OpenUrl
  34. 34.↵
    Sun YM, Yu HL, Zhou XY, et al. Disease Progression in Patients with Parkin-Related Parkinson’s Disease in a Longitudinal Cohort. Mov Disord. 2021;36(2):442–448.
    OpenUrl
  35. 35.
    Cao LX, Jiang Y, Piao YS, Huang Y. Rapid motor progression of Parkinson’s disease associates with clinical and genetic variants. Front Biosci (Landmark Ed). 2021;26(12):1503–1512.
    OpenUrl
  36. 36.↵
    Maple-Grodem J, Dalen I, Tysnes OB, et al. Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. Neurology. 2021;96(7):e1036–e1044.
    OpenUrlPubMed
  37. 37.↵
    Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. MAPT rs17649553 T allele is associated with better verbal memory and higher small-world properties in Parkinson’s disease. Neurobiol Aging. 2023;129:219–231.
    OpenUrl
  38. 38.↵
    Caminiti SP, Carli G, Avenali M, Blandini F, Perani D. Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson’s Disease Patients with GBA Mutations. Mov Disord. 2022;37(1):106–118.
    OpenUrl
  39. 39.↵
    Jesus S, Huertas I, Bernal-Bernal I, et al. GBA Variants Influence Motor and Non-Motor Features of Parkinson’s Disease. PLoS One. 2016;11(12):e0167749.
    OpenUrl
  40. 40.↵
    Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2-Asssociated Parkinson Disease Population. JAMA Neurol. 2018;75(3):312–319.
    OpenUrl
  41. 41.↵
    Trinh J, Zeldenrust FMJ, Huang J, et al. Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord. 2018;33(12):1857-1870.
    OpenUrl
  42. 42.↵
    Kilarski LL, Pearson JP, Newsway V, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson’s disease. Mov Disord. 2012;27(12):1522-1529.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Kasten M, Hartmann C, Hampf J, et al. Genotype-Phenotype Relations for the Parkinson’s Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Mov Disord. 2018;33(5):730-741.
    OpenUrlCrossRef
  44. 44.↵
    Bakhit Y, Ibrahim MO, Tesson C, et al. Intrafamilial and interfamilial heterogeneity of PINK1-associated Parkinson’s disease in Sudan. Parkinsonism Relat Disord. 2023;111:105401.
  45. 45.↵
    Koros C, Stamelou M, Simitsi A, et al. Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD. Neurology. 2018;90(10):e864–e869.
    OpenUrl
  46. 46.↵
    Petrucci S, Ginevrino M, Trezzi I, et al. GBA-Related Parkinson’s Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. Mov Disord. 2020;35(11):2106–2111.
    OpenUrl
  47. 47.↵
    Ren J, Zhang R, Pan C, et al. Prevalence and genotype-phenotype correlations of GBA-related Parkinson disease in a large Chinese cohort. Eur J Neurol. 2022;29(4):1017–1024.
    OpenUrl
  48. 48.↵
    Wang G, Huang Y, Chen W, et al. Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson’s disease. Parkinsonism Relat Disord. 2016;24:89–94.
    OpenUrl
  49. 49.↵
    Si QQ, Yuan YS, Zhi Y, et al. SNCA rs11931074 polymorphism correlates with spontaneous brain activity and motor symptoms in Chinese patients with Parkinson’s disease. J Neural Transm (Vienna). 2019;126(8):1037–1045.
    OpenUrl
  50. 50.↵
    Shen YT, Wang JW, Wang M, et al. BST1 rs4698412 allelic variant increases the risk of gait or balance deficits in patients with Parkinson’s disease. CNS Neurosci Ther. 2019;25(4):422–429.
    OpenUrl
  51. 51.↵
    Tan MMX, Lawton MA, Jabbari E, et al. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson’s Disease. Mov Disord. 2021;36(2):424–433.
    OpenUrlPubMed
  52. 52.↵
    Deng X, Xiao B, Allen JC, et al. Parkinson’s disease GWAS-linked Park16 carriers show greater motor progression. J Med Genet. 2019;56(11):765–768.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    Webb J, Willette AA. Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson’s disease clinical severity. Neurobiol Aging. 2017;50:39–46.
    OpenUrlCrossRefPubMed
  54. 54.↵
    Pu JL, Jin CY, Wang ZX, et al. Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson’s Disease. Mov Disord. 2022;37(1):196–200.
    OpenUrl
  55. 55.↵
    Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. Parkinson’s disease-associated genetic variants synergistically shape brain networks. medRxiv. 2023:2022.2012.2025.22283938.
  56. 56.↵
    Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. Age and sex differentially shape brain networks in Parkinson’s disease. CNS Neurosci Ther. 2023;29(7):1907–1922.
    OpenUrl
  57. 57.↵
    Yue X, Li Z, Li Y, et al. Altered Static and Dynamic Functional Network Connectivity in Post-stroke Cognitive Impairment. Neurosci Lett. 2023:137097.
  58. 58.
    Lesourd M, Reynaud E, Navarro J, et al. Involvement of the posterior tool processing network during explicit retrieval of action tool and semantic tool knowledge: an fMRI study. Cereb Cortex. 2023.
  59. 59.
    Chaddock-Heyman L, Weng TB, Kienzler C, et al. Scholastic performance and functional connectivity of brain networks in children. PLoS One. 2018;13(1):e0190073.
    OpenUrl
  60. 60.↵
    Wu GR, Stramaglia S, Chen H, Liao W, Marinazzo D. Mapping the voxel-wise effective connectome in resting state FMRI. PLoS One. 2013;8(9):e73670.
    OpenUrlCrossRefPubMed
  61. 61.↵
    Wang J, Wang X, Xia M, Liao X, Evans A, He Y. GRETNA: a graph theoretical network analysis toolbox for imaging connectomics. Front Hum Neurosci. 2015;9:386.
    OpenUrlCrossRefPubMed
  62. 62.↵
    Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and interpretations. Neuroimage. 2010;52(3):1059–1069.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    Wang JH, Zuo XN, Gohel S, Milham MP, Biswal BB, He Y. Graph theoretical analysis of functional brain networks: test-retest evaluation on short- and long-term resting-state functional MRI data. PLoS One. 2011;6(7):e21976.
    OpenUrlCrossRefPubMed
  64. 64.↵
    Zalesky A, Fornito A, Bullmore ET. Network-based statistic: identifying differences in brain networks. Neuroimage. 2010;53(4):1197–1207.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.↵
    Benjamini Y, Yekutieli D. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. 1995;57(1):289–300.
    OpenUrlCrossRefWeb of Science
  66. 66.↵
    Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord. 2014;20(1):99–105.
    OpenUrlCrossRefPubMed
  67. 67.↵
    Luth T, Konig IR, Grunewald A, et al. Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors. Mov Disord. 2020;35(10):1854–1858.
    OpenUrlCrossRef
  68. 68.↵
    Gabbert C, Konig IR, Luth T, et al. Lifestyle factors and clinical severity of Parkinson’s disease. Sci Rep. 2023;13(1):9537.
    OpenUrl
  69. 69.↵
    Lai D, Alipanahi B, Fontanillas P, et al. Genomewide Association Studies of LRRK2 Modifiers of Parkinson’s Disease. Ann Neurol. 2021;90(1):76–88.
    OpenUrlCrossRef
  70. 70.↵
    Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281–7289.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    Hall S, Surova Y, Ohrfelt A, et al. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease. Mov Disord. 2016;31(6):898–905.
    OpenUrl
  72. 72.↵
    Engelender S, Isacson O. The Threshold Theory for Parkinson’s Disease. Trends Neurosci. 2017;40(1):4–14.
    OpenUrlCrossRef
  73. 73.↵
    de Franciscis S, Johnson S, Torres JJ. Enhancing neural-network performance via assortativity. Phys Rev E Stat Nonlin Soft Matter Phys. 2011;83(3 Pt 2):036114.
    OpenUrlPubMed
  74. 74.↵
    Pechenick DA, Payne JL, Moore JH. The influence of assortativity on the robustness of signal-integration logic in gene regulatory networks. J Theor Biol. 2012;296:21–32.
    OpenUrlPubMed
  75. 75.↵
    Roy M, Poria S, Hens C. Assortativity-induced explosive synchronization in a complex neuronal network. Phys Rev E. 2021;103(6-1):062307.
    OpenUrl
  76. 76.↵
    Wang E, Jia Y, Ya Y, et al. Abnormal Topological Organization of Sulcal Depth-Based Structural Covariance Networks in Parkinson’s Disease. Front Aging Neurosci. 2020;12:575672.
  77. 77.
    Vo A, Schindlbeck KA, Nguyen N, et al. Adaptive and pathological connectivity responses in Parkinson’s disease brain networks. Cereb Cortex. 2023;33(4):917–932.
    OpenUrl
  78. 78.↵
    Tang Y, Xiao X, Xie H, et al. Altered Functional Brain Connectomes between Sporadic and Familial Parkinson’s Patients. Front Neuroanat. 2017;11:99.
  79. 79.↵
    Luo N, Sui J, Abrol A, et al. Structural Brain Architectures Match Intrinsic Functional Networks and Vary across Domains: A Study from 15 000+ Individuals. Cereb Cortex. 2020.
  80. 80.
    Lawrence AJ, Tozer DJ, Stamatakis EA, Markus HS. A comparison of functional and tractography based networks in cerebral small vessel disease. Neuroimage Clin. 2018;18:425–432.
    OpenUrl
  81. 81.
    Nestor SM, Misic B, Ramirez J, et al. Small vessel disease is linked to disrupted structural network covariance in Alzheimer’s disease. Alzheimers Dement. 2017;13(7):749–760.
    OpenUrl
  82. 82.↵
    Gong G, He Y, Chen ZJ, Evans AC. Convergence and divergence of thickness correlations with diffusion connections across the human cerebral cortex. Neuroimage. 2012;59(2):1239–1248.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    van Noort V, Snel B, Huynen MA. The yeast coexpression network has a small-world, scale-free architecture and can be explained by a simple model. EMBO Rep. 2004;5(3):280–284.
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    Le DH. Network-based ranking methods for prediction of novel disease associated microRNAs. Comput Biol Chem. 2015;58:139–148.
    OpenUrl
  85. 85.↵
    Bork P, Jensen LJ, von Mering C, Ramani AK, Lee I, Marcotte EM. Protein interaction networks from yeast to human. Curr Opin Struct Biol. 2004;14(3):292–299.
    OpenUrlCrossRefPubMedWeb of Science
  86. 86.↵
    Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10(3):186–198.
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.↵
    Shin JH, Shin SA, Lee JY, Nam H, Lim JS, Kim YK. Precuneus degeneration and isolated apathy in patients with Parkinson’s disease. Neurosci Lett. 2017;653:250–257.
    OpenUrl
  88. 88.↵
    Dusek P, Jech R, Sieger T, et al. Abnormal activity in the precuneus during time perception in Parkinson’s disease: an fMRI study. PLoS One. 2012;7(1):e29635.
    OpenUrlCrossRefPubMed
  89. 89.
    Thibes RB, Novaes NP, Lucato LT, et al. Altered Functional Connectivity Between Precuneus and Motor Systems in Parkinson’s Disease Patients. Brain Connect. 2017;7(10):643–647.
    OpenUrl
  90. 90.↵
    Jia X, Li Y, Li K, Liang P, Fu X. Precuneus Dysfunction in Parkinson’s Disease With Mild Cognitive Impairment. Front Aging Neurosci. 2018;10:427.
  91. 91.↵
    Shang S, Zhu S, Wu J, et al. Topological disruption of high-order functional networks in cognitively preserved Parkinson’s disease. CNS Neurosci Ther. 2023;29(2):566–576.
    OpenUrl
  92. 92.↵
    Wei L, Zhang J, Long Z, et al. Reduced topological efficiency in cortical-basal Ganglia motor network of Parkinson’s disease: a resting state fMRI study. PLoS One. 2014;9(10):e108124.
    OpenUrlCrossRef
  93. 93.↵
    Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. BIN3 rs2280104 T allele is associated with excessive daytime sleepiness and altered network topology in Parkinson’s disease. medRxiv. 2023:2023.2007.2017.23292760.
  94. 94.↵
    Luo CY, Guo XY, Song W, et al. Functional connectome assessed using graph theory in drug-naive Parkinson’s disease. J Neurol. 2015;262(6):1557–1567.
    OpenUrlCrossRefPubMed
  95. 95.↵
    Zhang D, Wang J, Liu X, Chen J, Liu B. Aberrant Brain Network Efficiency in Parkinson’s Disease Patients with Tremor: A Multi-Modality Study. Front Aging Neurosci. 2015;7:169.
  96. 96.↵
    Hou Y, Wei Q, Ou R, Yang J, Gong Q, Shang H. Impaired topographic organization in Parkinson’s disease with mild cognitive impairment. J Neurol Sci. 2020;414:116861.
  97. 97.↵
    Fang J, Chen H, Cao Z, et al. Impaired brain network architecture in newly diagnosed Parkinson’s disease based on graph theoretical analysis. Neurosci Lett. 2017;657:151–158.
    OpenUrlCrossRef
  98. 98.
    Bejr-Kasem H, Pagonabarraga J, Martinez-Horta S, et al. Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson’s disease. Mov Disord. 2019;34(1):78–86.
    OpenUrlCrossRef
  99. 99.
    Chen L, Huang T, Ma D, Chen YC. Altered Default Mode Network Functional Connectivity in Parkinson’s Disease: A Resting-State Functional Magnetic Resonance Imaging Study. Front Neurosci. 2022;16:905121.
  100. 100.↵
    Szewczyk-Krolikowski K, Menke RA, Rolinski M, et al. Functional connectivity in the basal ganglia network differentiates PD patients from controls. Neurology. 2014;83(3):208–214.
    OpenUrlCrossRefPubMed
  101. 101.↵
    Humphries MD, Obeso JA, Dreyer JK. Insights into Parkinson’s disease from computational models of the basal ganglia. J Neurol Neurosurg Psychiatry. 2018;89(11):1181–1188.
    OpenUrlAbstract/FREE Full Text
  102. 102.↵
    Neumann WJ, Schroll H, de Almeida Marcelino AL, et al. Functional segregation of basal ganglia pathways in Parkinson’s disease. Brain. 2018;141(9):2655–2669.
    OpenUrlCrossRef
  103. 103.↵
    Krishna V, Fishman PS, Eisenberg HM, et al. Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinson’s Disease. N Engl J Med. 2023;388(8):683–693.
    OpenUrl
  104. 104.↵
    Ramirez-Zamora A, Ostrem JL. Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease: A Review. JAMA Neurol. 2018;75(3):367–372.
    OpenUrl
  105. 105.↵
    East MP, Laitinen T, Asquith CRM. BCKDK: an emerging kinase target for metabolic diseases and cancer. Nat Rev Drug Discov. 2021;20(7):498.
    OpenUrl
  106. 106.↵
    Xue P, Zeng F, Duan Q, et al. BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer. EBioMedicine. 2017;20:50–60.
    OpenUrl
  107. 107.↵
    Tian Q, Yuan P, Quan C, et al. Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer. Oncogene. 2020;39(20):3980–3996.
    OpenUrlCrossRef
  108. 108.↵
    Grenier-Larouche T, Coulter Kwee L, Deleye Y, et al. Altered branched-chain alpha-keto acid metabolism is a feature of NAFLD in individuals with severe obesity. JCI Insight. 2022;7(15).
  109. 109.↵
    Novarino G, El-Fishawy P, Kayserili H, et al. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science. 2012;338(6105):394–397.
    OpenUrlAbstract/FREE Full Text
  110. 110.
    Garcia-Cazorla A, Oyarzabal A, Fort J, et al. Two novel mutations in the BCKDK (branched-chain keto-acid dehydrogenase kinase) gene are responsible for a neurobehavioral deficit in two pediatric unrelated patients. Hum Mutat. 2014;35(4):470–477.
    OpenUrlCrossRefPubMed
  111. 111.
    Cheon S, Kaur K, Nijem N, et al. The ubiquitin ligase UBE3B, disrupted in intellectual disability and absent speech, regulates metabolic pathways by targeting BCKDK. Proc Natl Acad Sci U S A. 2019;116(9):3662–3667.
    OpenUrlAbstract/FREE Full Text
  112. 112.↵
    Tangeraas T, Constante JR, Backe PH, et al. BCKDK deficiency: a treatable neurodevelopmental disease amenable to newborn screening. Brain. 2023;146(7):3003–3013.
    OpenUrl
  113. 113.↵
    Yu JY, Cao N, Rau CD, et al. Cell-autonomous effect of cardiomyocyte branched-chain amino acid catabolism in heart failure in mice. Acta Pharmacol Sin. 2023;44(7):1380–1390.
    OpenUrl
  114. 114.↵
    Uddin GM, Zhang L, Shah S, et al. Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. Cardiovasc Diabetol. 2019;18(1):86.
    OpenUrlCrossRefPubMed
  115. 115.↵
    Wang L, Li NN, Lu ZJ, et al. Association of three candidate genetic variants in ACMSD/TMEM163, GPNMB and BCKDK /STX1B with sporadic Parkinson’s disease in Han Chinese. Neurosci Lett. 2019;703:45–48.
    OpenUrlCrossRef
  116. 116.↵
    Heckman MG, Kasanuki K, Diehl NN, et al. Parkinson’s disease susceptibility variants and severity of Lewy body pathology. Parkinsonism Relat Disord. 2017;44:79–84.
    OpenUrlCrossRef
  117. 117.↵
    Dang X, Zhang Z, Luo XJ. Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Nominates Potential Causal Genes for Parkinson’s Disease. Mov Disord. 2022;37(12):2451–2456.
    OpenUrl
  118. 118.↵
    Soutar MPM, Melandri D, O’Callaghan B, et al. Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at 16q11.2 and MAPT H1 loci. Brain. 2022;145(12):4349–4367.
    OpenUrl
  119. 119.↵
    Li CY, Ou RW, Chen YP, et al. Genetic Analysis of ZNF Protein Family Members for Early-Onset Parkinson’s Disease in Chinese Population. Mol Neurobiol. 2021;58(7):3435–3442.
    OpenUrl
  120. 120.↵
    Zhang H, Yang L, Feng Q, Fan Y, Zheng H, He Y. Association between VKORC1 gene polymorphisms and ischemic cerebrovascular disease in Chinese Han population. J Mol Neurosci. 2014;53(2):166–170.
    OpenUrl
  121. 121.↵
    Mur J, McCartney DL, Chasman DI, et al. Variation in VKORC1 Is Associated with Vascular Dementia. J Alzheimers Dis. 2021;80(3):1329–1337.
    OpenUrl
  122. 122.↵
    Marioni RE, Harris SE, Zhang Q, et al. GWAS on family history of Alzheimer’s disease. Transl Psychiatry. 2018;8(1):99.
    OpenUrl
Back to top
Posted July 26, 2023.
Download PDF

Supplementary Material

Email
BCKDK rs14235 A allele is associated with milder motor impairment and altered network topology in Parkinson’s disease
Zhichun Chen, Bin Wu, Guanglu Li, Liche Zhou, Lina Zhang, Jun Liu
medRxiv 2023.07.20.23292985; doi: https://doi.org/10.1101/2023.07.20.23292985
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area